

ABSTRACT OF THE DISCLOSURE

The use of anti-idiotypic antibodies of the fibroblast growth factor (1) and/or anti-idiotypic antibodies of fibroblastic growth factor (2), for preparing a medicine for treating pathologies involving endothelial cells implied in an angiogenic process, either for inhibiting angiogenesis, or for promoting angiogenesis, without affecting the quiescent endothelial cells, or for preparing a diagnostic product for pathologies involving endothelial cells implied in an angiogenic process.